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The blood brain barrier (BBB) is often regarded as a passive barrier that protects brain
parenchyma from toxic substances, circulating leukocytes, while allowing the passage
of selected molecules. Recently, a combination of molecular profiling techniques have
characterized the constituents of the BBB based on in vitro models using isolated
endothelial cells and ex vivo models analyzing isolated blood vessels. Characterization
of gene expression profiles that are specific to the endothelium of brain blood vessels,
and the identification of proteins, cells and multi-cellular structure that comprise the
BBB have led to a emerging consensus that the BBB is not, in and of itself, a simple
barrier of specialized endothelial cells. Instead, regulation of transcytosis, permeability,
and drug translocation into the central nervous system is now viewed as a collection of
neurovascular units (NVUs) that, together, give the BBB its unique biological properties.
We will review recent technology advancing the understanding of the molecular basis of
the BBB with a focus on proteomic approaches.
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The focus of this review is on techniques that can be applied to the analysis of in vivomodels with
particular attention to the complementary value of transcriptomics (Enerson and Drewes, 2006;
Daneman et al., 2010) where sensitivity and standardized analytical techniques in RNA expression
are powerful tools that can provide optimal coverage of gene expression in select tissues and cell
types. Furthermore, we address the challenges of analyzing the protein composition of the BBB
from the perspective of not only the endothelial cells, a compartment that has been the focus of
in vitro models, but also the importance of considering the BBB as a multicellular structure with
extracellular matrix (ECM) and other cell types relevant in BBB formation (Chun et al., 2011; Hoshi
et al., 2013; Badhwar et al., 2014).
Proteomics for Blood Brain Barrier Interrogation
Proteomics, the global interrogation of the protein population expressed by a genome, cells,
or tissue types, makes use of biochemical and physical methods to determine the iden-
tity of proteins present (Yates, 1998, 2000; Banks et al., 2000; McDonald and Yates, 2000;
Pandey and Mann, 2000; Yates, 2000; Mann and Pandey, 2001; Mann et al., 2001). Proteomics
Abbreviations: BBB, Blood brain barrier; NVU, neurovascular unit; MudPIT, multi-dimensional protein identiﬁcation tech-
nology; ECM, extracellular matrix; iTRAQ, Tags for Relative and Absolute Quantitation; TMT, Tandem Mass Tags; AQP4,
Aquaporin 4; GFAP, glial ﬁbrillary acidic protein; CW, circle of Willis.
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is complementary to studies of gene expression. Determination
of the changes in cellular mRNA abundance provides infor-
mation on gene activity and the cellular state (Enerson and
Drewes, 2006; Daneman et al., 2010). For many genes, changes
in mRNA abundance correspond to changes in protein abun-
dance (Yates, 1998; Banks et al., 2000; McDonald and Yates,
2000; Pandey and Mann, 2000; Yates, 2000; Mann and Pandey,
2001; Mann et al., 2001). However, protein-based cellular anal-
ysis is essential to establish the translation of mRNAs to pro-
teins, since mRNAs have varying stability, translational eﬃciency
and do not address post-translational modiﬁcations. The diverse
chemical properties of proteins make them diﬃcult to separate
and identify. Two-dimensional gel electrophoresis has been the
standard for separation, isolation, and sequencing of individual
proteins from sera, cells, and tissues for more than 25 years.
However, this methodology does not provide high through-
put protein identiﬁcation and quantiﬁcation required for the
study of the cellular proteome. What revolutionized the pro-
teomic ﬁeld was the development of mass spectrometry instru-
mentation capable of rapidly and reproducibly fragmenting pep-
tides and bioinformatic software to match the observed peptide
fragment masses to a database of predicted masses for one of
many given peptide sequences (Washburn et al., 2001; Wu et al.,
2003).
Shotgun proteomics or Multi-Dimensional Protein Identi-
ﬁcation Technology (MudPIT) is the contemporary approach
for identifying proteins in complex cellular samples (Washburn
et al., 2001; Wu and Maccoss, 2002; Wu et al., 2003; Kislinger
et al., 2005; Yates et al., 2009). Themethodology relies on protease
digestion of the cellular protein sample to peptides, followed by
peptide separation on inline high performance chromatography,
and identiﬁcation of the peptides by tandem mass spectrometry
(Chun et al., 2011; Hoshi et al., 2013; Badhwar et al., 2014). The
uniqueness of the mass fragmentation of each peptide is used
to identify the protein from which it was derived (Chun et al.,
2011; Hoshi et al., 2013; Badhwar et al., 2014). The advantage
of MudPIT, over classical two dimensional gel analyses, is the
better resolving power, enabling a more precise protein quantiﬁ-
cation and identiﬁcation of a larger number of proteins from the
complex proteome of isolated tissues or cells (Washburn et al.,
2001; Aebersold and Mann, 2003; Wu et al., 2003; Pottiez et al.,
2009). In addition to being useful for tissues, such techniques
are sensitive enough for use on desired cell populations isolated
by ﬂow cytometry or magnetic beads. Importantly, the increas-
ing resolving power of the mass spectrometers, highly curated
and annotated databases for protein identiﬁcation, and bioinfor-
matic to identify proteins from databases, provides the researcher
with powerful methods to analyze complex cellular protein mix-
tures (Chen et al., 2006; Ruse et al., 2008; Gonzalez-Begne et al.,
2009).
In contrast to transcriptomics methodology, which takes
advantage of chemical similarity among RNAs allowing quantiﬁ-
cation among experimental samples, quantiﬁcation of proteins in
complex protein samples are hindered by the diverse chemical
nature of proteins and the resolving power of mass spectrometers
(Coombs, 2011). One method for relative protein quantiﬁcation
from diﬀerent experimental samples (i.e., control vs. tests) in an
experimental study relies on a label-free approach of determin-
ing peptide abundance through spectral counting in each sample,
thereby allowing comparison among the experimental samples
(Florens et al., 2006; Mueller et al., 2008; Neilson et al., 2011;
Nahnsen et al., 2013). A more precise method for determining
the relative abundance of proteins from experimental samples is
to label proteins in each experimental sample with a unique sta-
ble isotope, thereby allowing the mass spectrometer to identify
identical proteins with diﬀerent masses (McDonald and Yates,
2000; Wu et al., 2004; Gouw et al., 2008; Liao et al., 2008; Uchida
et al., 2013). The diﬀerentially isotope labeled samples are com-
bined and analyzed together and the relative abundance of each
protein in the mixture can be determined. Examples of these
methods are Stable Isotope Labeling with Amino acids in cell
Culture (SILAC), which relies on labeling of proteins in cellular
samples by metabolic labeling with 15N where the diﬀerential in
15N/14N labeling can be used to quantify the relative abundance
of identical proteins grown under diﬀerent conditions (Wu et al.,
2004; Lu et al., 2007; Gouw et al., 2008; Haqqani et al., 2008;
Kamiie et al., 2008; Liao et al., 2008; Evans et al., 2012). This
approach and other related metabolic cell labeling technologies
are powerful tools where the model system, either cell culture or
an animal, can be metabolically labeled to enable absolute quan-
tiﬁcation based on the relative uptake of labeled isotopes. The
application of these approaches for the annotation of protein and
nucleotide databases underscores the importance of multidisci-
plinary technologies to better understand correlations between
gene expression and protein translation (Mann and Pandey, 2001;
Mann et al., 2001; Ohtsuki et al., 2011; Uchida et al., 2013). Addi-
tional quantitative techniques that have been previously reviewed
include labeling of a peptide mixture with N-terminal or reactive
amines using deﬁned molecular tags, termed Isobaric Tags for
Relative and Absolute Quantitation (iTRAQ) and Tandem Mass
Tag (TMT) (Wu et al., 2004; Gouw et al., 2008; Christoforou and
Lilley, 2012; Evans et al., 2012; Geillinger et al., 2012; Ivancic et al.,
2013).
Protein Prioritization Based on Functional
Interactions between Capillaries, Glia,
Neurons, and the Basal Lamina
The BBB is generally regarded as a passive barrier that protects
brain parenchyma from toxic substances. Vascular biologists
studying BBB function have often ignored the neuronal compo-
nents present in freshly isolated tissues and turned to endothelial
cell models separated from the endogenous neuronal-astrocytic
milieu. In some cases, cell models were derived from diﬀerent cell
types altogether to represent the BBB. However, over the course
of the last several years, a general consensus has emerged that
the BBB is not a simple barrier of specialized endothelial cells
controlling transcytosis, permeability and drug translocation into
the CNS (Neuwelt et al., 2008; Abbott, 2013) (Figure 1). Rather,
the BBB is now correctly viewed as a collection of neurovascu-
lar units (NVUs) that, together, give the BBB its unique features
(Abbott et al., 2006; Cecchelli et al., 2007; Hermann and Elali,
2012; Elali et al., 2014). NVUs are localized throughout the CNS.
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In larger microvessels (e.g., arterioles), the NVU is composed of
endothelial cells, Aquaporin 4-positive (AQP4+) feet vs. GFAP
positive (GFAP+) astrocytes, and neuronal projections. These
interactions can regulate vasodilation in arterioles (i.e., neurovas-
cular coupling) in contrast to capillary endothelial cells that have
no direct neuronal projections (Simard et al., 2003). A more pre-
cise description of the NVU requires consideration of the direct
interactions of AQP4+ GFAP− astrocyte end-feet upon capil-
lary endothelial cells (Chun et al., 2011). These AQP4+ GFAP−
astrocytes are an important class of astrocytes that are in contact
with a basal lamina that envelopes the outer surface brain capil-
lary (Muldoon et al., 1999; Simard et al., 2003). Furthermore, the
isolation and analysis of intact microvessels from mouse brain
identiﬁes extracellular matrix (ECM) proteins expressed in the
blood vessel microenvironment, many of which are known to
FIGURE 1 | A model of the neurovascular unit in capillaries. Proteomic
technologies that focus on the protein components of brain endothelial cells
and associated astrocytes from intact capillaries identify basal lamina
components that are under-represented in purified cells (Chun et al., 2011).
In contrast, Proteomic analyses of purified cells yields quantitative and
definitive cell type specific protein expression (Reviewed in Table 1).
be basal lamina proteins (Chun et al., 2011). Table 1 summa-
rizes the approaches for isolation of blood vessels for proteomics
studies where the focus is on the analysis of isolated brain blood
vessels. These proteomic data sets allow for comparisons with
data sets obtained from cultured brain endothelium, where the
absence of ECM microenvironment and supporting cells of the
NVIU limits the translation to physiological context. We pro-
pose that this model of the NVU should be front and center for
prioritization of analysis of proteins identiﬁed by proteomic tech-
nologies. Speciﬁcally, physiological context can be used to cate-
gorize various proteins that may be identiﬁed as a consequence
of increased/decreased BBB integrity based on the presence of
various speciﬁc cell types and their response to local or distal
stimuli.
Proteomics Approaches Based on Isolated
Blood Vessels
Since the BBB is in fact a multicellular structure, with essential
ECM contributions to the organization and maintenance of the
BBB integrity, arguably it is the proteomic analyses of intact
brain blood vessels from human, rat, and mouse where the
signiﬁcant growth opportunity is present for the BBB pro-
teomics community in the coming years. As with any molec-
ular proﬁling technology, attention to the technical details,
and quality control of the isolation method are critical to the
relevance of the data sets obtained. For example, the emer-
gence of multiple techniques from diﬀerent groups has enabled
the cross-comparison between mouse capillaries and mouse
arteries to assess diﬀerences in the vascular phenotypes in
the brain that have distinct biological functions (Enerson and
Drewes, 2006; Daneman et al., 2010; Chun et al., 2011; Oht-
suki et al., 2013; Badhwar et al., 2014). For example, the emerg-
ing importance of extracellular microvesicles in intercellular
communication in BBB biology has been recently addressed
with proteomics, advancing the understanding of the compo-
sition of an organelle that is under-represented in the BBB
literature (Simpson et al., 2008; Haqqani et al., 2013). Further-
more, these studies have provided speciﬁc methods that cross-
validate the methods used for vessel isolation and proteomic
analysis.
TABLE 1 | List of proteomic studies using isolated brain blood vessels.
Species Source Isolation method Analytical method References
Human Microvessels Density gradient LC-MS/MS with in silico selection Uchida et al., 2011
Mouse Microvessels Glass bead LC-MS/MS MudPIT Chun et al., 2011
Mouse Microvessels Glass bead Tag labeling/LC-MS/MS Uchida et al., 2013
Mouse Artery Microdissection LC-MS/MS MudPIT Badhwar et al., 2014
Rat Vessels Laser capture ICAT with LC-MS/MS Haqqani et al., 2005
Mouse Vessels Laser capture Gel/Fourier transform MS Murugesan et al., 2011
Marmoset Microvessels Density gradient Tag labeling/LC-MS/MS Hoshi et al., 2013
Rat Microvessels Density Gradient Tag labeling/LC-MS/MS Hoshi et al., 2013
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In the study by Chun et al. (2011), the focus was on the iden-
tiﬁcation of membrane proteins and ECM proteins. The char-
acterization of membrane proteins from isolated blood vessels
vs. cultured endothelial studies enables comparison of proteins
between intact in vivo models and more established, homoge-
nous and quantitative assays in vitro using cultured endothelial
cells. Expression of membrane transporter proteins validates the
identiﬁcation of ECM proteins that comprise the basal lamina, a
class of proteins that is otherwise generally under-represented in
RNA studies of microvessels, likely diﬀerent from the ECM pro-
teins expressed in endothelial cells cultured on plastic. Finally,
the report on cell type-speciﬁc RNA expression in endothelial
cells vs. associated astrocytes (Daneman et al., 2010) enables
the classiﬁcation of proteins based on the relative expression
of the RNA that likely predicts protein expression. So while
RNA expression is an imperfect assessment of protein expres-
sion proﬁles, the alternate proteomic techniques are comple-
mentary. The application of MudPIT to the analysis of primary
mouse brain microvessels, isolated from the mouse cortex using
the glass bead technique (Hartz et al., 2006; Yousif et al., 2007),
established a mouse protein expression resource that can be
compared with other methods. Chun et al. (2011), based their
original approach on the initial work of Enerson and Drewes
(2006) in the characterization of the isolated rat microvessel
transcriptome, which was used as a foundation for the cross-
comparison with transcriptome of isolated endothelial cells and
astrocytes, and protein expression of transporters (Chun et al.,
2011).
Vessel Heterogeneity
In the recent study by Badhwar et al. (2014), mouse brain
arteries were dissected from the circle of Willis (CW) structure
formed at the conﬂuence of the internal carotid arteries, a por-
tion of the vertebrobasilar artery and branching arteries. The
goal of this study was to determine the protein expression pro-
ﬁle of a CW, a vascular structure that is critical to the perfu-
sion of deep cortical regions of the brain, which are aﬀected by
aging and neurodenegerative disorders associated with changes
in vessel wall thickness and elasticity. The microsurgical iso-
lation of the CW arteries in the mouse provides for a highly
enriched starting material for MudPIT analysis, with a com-
paratively homogenous vascular phenotype. In this study both
gel-based and gel-free (i.e., strong cation exchange chromatog-
raphy) followed by tandem mass spectrometry were performed
to obtain a comprehensive resource for mouse CW arterial ves-
sels (Badhwar et al., 2014). Proteins identiﬁed by MudPIT were
validated by Western blot analysis and exhaustively compared
with the mouse microvascular proteome published by Chun et al.
(2011), and were annotated with common and unique proteins
in each dataset listed (Badhwar et al., 2014). The PANTHER clas-
siﬁcation identiﬁed proteins as blood-brain barrier-speciﬁc cell
type proteins, tight junction and adhesion proteins, membrane
transporter and channel proteins, and ECM and basal lamina
proteins (Mi et al., 2013). In each case identiﬁed proteins were
veriﬁed for their detection in previously reported mouse and rat
transcriptome studies. Protein components related to signaling
pathways, vasoactivity, arterial proteins, and neuronal proteins
and were also identiﬁed.
Proteomic Analyses in Disease and Animal
Models
The cross-comparison of this arterial vessel resource with
microvessels provides an important database in which to ana-
lyze the eﬀects of genetic mutants and (Agarwal et al., 2012)
injury/tumor models that impact cerebrovascular biology. As
more proteomic studies are completed the more comprehensive
the datasets will be for the researcher. Based on the isolation
of intact brain blood vessels from mice, recently characterized
mouse mutant studies can be further analyzed and compared
with isolation techniques such as laser capture microdissection,
and analytical techniques based on gel electrophoresis, and cul-
tured endothelial cells. Laser microdissection enables the isola-
tion of discrete structures enriched in speciﬁc cell types that can
be analyzed for gene expression with a high degree of sensitivity
as well as proteomics using mass spectrometry (Haqqani et al.,
2005; Murugesan et al., 2011). The power of such techniques
complements the isolation of microvessels and arteries and pro-
vides opportunities to further characterize knockoutmousemod-
els, such as the P-gp/Bcrp mouse model (Agarwal et al., 2009,
2012).
Lastly, the challenges of determining diﬀerences in rodent
vs. primate protein constituents of the blood brain barrier
(BBB) have been recently addressed by Hoshi et al. (2013),
where isolated blood vessels from rats and marmosets were
subjected to MudPIT using a quantitative approach based on
an in silico peptide selection. In this model, side-by-side com-
parison of rat vs. marmoset data sets with human proteins
related to endothelial cell-related membrane transporters, recep-
tors and tight junction proteins revealed several interesting
insights. Signiﬁcant 2 fold diﬀerences in several key transporters
were observed between rat and human blood vessels (Hoshi
et al., 2013). Interestingly few signiﬁcant changes in transporters
between human and marmoset blood vessels were observed,
suggesting that marmosets may be a useful tool for studying
select brain blood vessel proteins that are substantially diﬀer-
ent between rodents and humans (Hoshi et al., 2013). This
study is an excellent example of the power of the quantitative
approach to deﬁne more precisely the expression proﬁle of cell
membrane transporters that have relevance to drug develop-
ment.
As themethodology and bioinformatics improve for both pro-
teomics and transcriptomics it may soon be possible to correlate
relative levels of gene expression with protein changes (Wang
et al., 2014). The focused application of such technologies will
enable a more complete understanding of the role of secreted fac-
tors (i.e., exosomes, growth factors) and how these components
may condition the basal lamina and signal to associated cells in
disease.
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